An announcement from Innovent Biologics ( ($HK:1801) ) is now available. Innovent Biologics has announced the approval of SYCUME®, China’s first ...

Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of ...

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody ...

The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal ...

Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of ...

As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...

SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...